InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,071.63
(
0.02%
)
US TECH 100
16,913.20
(
-0.86%
)
Dow Jones
38,460.92
(
-0.11%
)
Brent Oil
87.31
(
0.10%
)
Bitcoin
63,838.93
(
-0.69%
)
Post# of 712
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

RNsidersbuying

Send PM Follow Ignore
Followers 46
Posts 4446
Boards Moderated 0
Alias Born 07/26/2010

RNsidersbuying

Re: None

Tuesday, 09/08/2015 11:11:28 AM

Tuesday, September 08, 2015 11:11:28 AM

Post# of 712
SAN DIEGO, July 23, 2015 /PRNewswire/ -- Lpath, Inc. LPTN, +0.23% the industry leader in bioactive lipid-targeted therapeutics, announced that the U.S. Food and Drug Administration (FDA) has completed its review of the Investigational New Drug Application (IND) for Lpathomab™. The FDA informed the company that the Phase 1 clinical trial to study Lpathomab may now be initiated. Lpath plans to begin this trial upon investigational review board approvals and anticipates the first subject to be dosed within two months.

http://www.marketwatch.com/story/lpath-announces-plan-to-begin-lpathomab-clinical-trial-2015-07-23?siteid=bigcharts&dist=bigcharts

Expecting an update soon
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up